Cenobamate (Ontozry®, Xcopri®) is now listed in the interaction checker and can be found in the anticonvulsant class of comedications.
Cenobamate is a dose-dependent inducer of CYP3A4 and a strong inducing effect is expected with daily maintenance doses of 200 mg and greater.
